ICG-186

N/A

Report date: 2023/04/02 18:55:16

Base Information

Drug NameICG-186

Drug Alias NameAnti-BCMA chimeric antigen receptor T cell therapy (Guiqidan Biomedicine)

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesiCar Bio Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesiCar Bio Therapeutics Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A